Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer, Pharmacia Protest Inclusion Of Drug Innovator Data In "Paper NDAs"

Executive Summary

Pfizer and Pharmacia are requesting that FDA revise a draft guidance so that "paper NDAs" approved under section 505(b)(2) of the Waxman/Hatch patent law would not be allowed to rely on non-published studies conducted by the product innovator.
Advertisement

Related Content

BIO Petition Opposes Generic Insulin, HGH; Asks FDA To Open Public Debate
BIO Petition Opposes Generic Insulin, HGH; Asks FDA To Open Public Debate
Pfizer Norvasc Patent Term Extension Coverage: The Product Or The Use?
Pfizer Norvasc Patent Term Extension Coverage: The Product Or The Use?
Pfizer Norvasc Challenges: Mylan ANDA, Dr. Reddy’s 505(b)(2)
Generic Somatropin NDAs Would Require Human Immunogenicity Tests – FDA
Recombinant Drugs Too Complex For 505(b)(2), Should Go To CBER – Amgen
Ranbaxy Generic Ceftin May Clear FDA After USP Monograph Revision
Generics With Poor Bioavailability May Not Use 505(b)(2) "Paper" NDA
Generics With Poor Bioavailability May Not Use 505(b)(2) "Paper" NDA
Advertisement
UsernamePublicRestriction

Register

PS038374

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel